Business · 19/10/2016Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for PRILOSEC OTC
Summary
The FDA has published a notice determining the regulatory review period for PRILOSEC OTC, following a submission to the USPTO for patent extension of the human drug product.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →